Hemofiltration in Intensive Care

  • G. Berlot
  • M. Viviani
Conference paper


Since the very beginning of the medical era, the occurrence of several diseases has been attributed to the action of some endogenous or exogenous toxins, whose removal from the organism was warranted in order to re-establish a normal condition. Although in more-recent times this approach has been abandoned or largely modified, there is an ever-increasing number of clinical conditions associated with the presence of biologically active substances, whose accumulation can be considered either a marker of a determined disease (e.g., creatinine or urea during acute or chronic renal failure) or a causative agent (e.g. autoantibodies, immunocomplexes) [1]. The discovery of “toxic” subtances has prompted the development of purifying techniques such as he-modialysis (HD), peritoneal dialyis (PD), plasmapheresis (PP), and plasma exchange (PE), which have been and/or are currently used to treat different clinical conditions. In the critical care setting, in which both sepsis and acute renal failure (ARF) are particularly common and often associated with a poor prognosis, the blood purifying approach is particularly appealing. In the last 2 decades, several techniques have been aimed at removing fluids and waste products from the organism without creating cardiovascular problems. These techniques are based on convection, which implies the removal of electrolytes, urea, creatinine, and other waste products with microvolumes of plasma water [2, 3]. In the current scientific literature, convective-based techniques are described as ultrafiltration or hemofiltration.


Acute Renal Failure Septic Patient Continuous Renal Replacement Therapy Dialysis Fluid Continuous Venovenous Hemofiltration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Berlot G, Tomasini A, Silvestri L, Gullo A (1998) Plasmapheresis in the critically ill. Kidney Int 53[Suppl66]: 178–181Google Scholar
  2. 2.
    Bellomo R, Ronco C (1999) Continuous renal replacement therapy in the intensive care unit. Intensive Care Med 25: 781–789PubMedCrossRefGoogle Scholar
  3. 3.
    Forni IG, Hilton PJ (1997) Current concepts: continuous hemofiltration in the treatment of acute renal failure. N Engl J Med 336: 1303–1309PubMedCrossRefGoogle Scholar
  4. 4.
    Mallick NP, Gokal R (1999) Haemodialyis. Lancet 353: 737–742PubMedCrossRefGoogle Scholar
  5. 5.
    Port FK (1994) Morbidity and mortality in dialysis patients. Kidney Int 46: 1728–1737PubMedCrossRefGoogle Scholar
  6. 6.
    Dhondt A, Vanholder R, van Biesen W, Lameire N (2000) The removal of uremic toxins. Kidney Int 58[Suppl76]: S47–S59CrossRefGoogle Scholar
  7. 7.
    Bellomo R, Kearly Y, Parkin G et al (1991) Treatment of life-threatening lithium toxicity with continuous arterio-venous hemodiafiltration. Crit Care Med 19: 836–837PubMedCrossRefGoogle Scholar
  8. 8.
    Leblanc M, Pichette V, Madore F et al (1995) n-acetylprocainamide intoxication with torsade de pointes treated by high dialysate flow rate continuous arteriovenous hemodiafiltration. Crit Care Med 23: 589–593PubMedCrossRefGoogle Scholar
  9. 9.
    Mehta RL, McDonald BR, Aguilar MM, Ward DM (1990) Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 378: 976–981CrossRefGoogle Scholar
  10. 10.
    Langenecker-Kozek SA, Felfernig M, Werba A et al (1994) Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 27: 1774–1781Google Scholar
  11. 11.
    Langenecker-Kozek SA, Kettner SC, Ouismueller C et al (1998) Anticoagulation with prostaglandin El and unfractioned heparin during continuous venovenous hemofiltration. Crit Care Med 26: 1208–1212CrossRefGoogle Scholar
  12. 12.
    De Pont ANJM, Oudemans-van Straaten Roozendal KJ, Zandtsra DF (2000) Nadroparin vesrus dalteparin in high-volume, continuous venovenous hemofiltration: a double blind, randomized, crossover study. Crit Care Med 28: 421–425PubMedCrossRefGoogle Scholar
  13. 13.
    Davenport A, Will E, Davidson AM (1993) Improved cardiovascular stability during continous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 21: 328–338PubMedCrossRefGoogle Scholar
  14. 14.
    Tortorella G, Gonzi G, Zambrelli, P et al (1997) Continuous veno-venous hemofiltration in acute renal failure associated with heart failure. Cardiologia 42: 845–848PubMedGoogle Scholar
  15. 15.
    van Bommel EFH (1997) Should continuous renal replacement therapy be used for “non renal” indications in critically ill patients with shock? Resuscitation 33: 257–270PubMedCrossRefGoogle Scholar
  16. 16.
    Liano F, Junco E, Pascual J (1998) The spectrum of acute renal failure in the intensive care unit compared with that seen in other settings. Kidney Int 53[Suppl66]: S16–S24Google Scholar
  17. 17.
    Misset B, Timsit JF, Chevret S et al (1996) A randomized cross-over comparison of the hemodynamic response to intermittent hemodialysis and continuos hemofiltration in ICU patients with acute renal failure. Intensive Care Med 22: 742–746PubMedCrossRefGoogle Scholar
  18. 18.
    Storck M, Haiti WH, Zimmerer E, Inthorn D (1991) Comparison of pump-driven and spontaneous continuous hemofiltration in postoperative acute renal failure. Lancet 337: 452–455PubMedCrossRefGoogle Scholar
  19. 19.
    Ronco C, Bellomo R, Hormel P et al (2000) Effects of different doses in continuous veno-venous hemofiltration on outcomes of acute renal failure: a prospective, randomised trial. Lancet 355: 26–30CrossRefGoogle Scholar
  20. 20.
    Story DA, Ronco C, Bellomo R (1999) Trace element and vitamin concentrations and losses in critically ill patients treated with continuous venovenous haemofiltration. Crit Care Med 27: 220–223PubMedCrossRefGoogle Scholar
  21. 21.
    Schetz M, Ferdinande P, Van der Berghe G et al (1995) Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 21: 612–620PubMedCrossRefGoogle Scholar
  22. 22.
    Schrier RW, Abraham WT (1999) Mechanisms of disease: hormones and hemodynamics in heart failure. N Engl J Med 341: 577–585PubMedCrossRefGoogle Scholar
  23. 23.
    Baudoin SV, Wiggins J, Keogh BF et al (1993) Continuous veno-venous haemofiltration following cardio-plmonary bpass. Intensive Care Med 19: 290–293CrossRefGoogle Scholar
  24. 24.
    Adrie C, Pinsky MR (2000) The inflammatory balance in human sepsis. Intensive Care Med 26: 364–375PubMedCrossRefGoogle Scholar
  25. 25.
    Cain BS, Meldrum DR, Harken AH, McIntyre (1998) The physiologic basis for anticytokine clinical trials in the treatment of sepsis. J Am Coll Surg 186: 337–350PubMedCrossRefGoogle Scholar
  26. 26.
    De Vriese AS, Vanholder RC, Pascual M et al (1999) Can inflammatory cytokine be removed efficiently by continuous renal replacement therapies? Intensive Care Med 25: 903–910PubMedCrossRefGoogle Scholar
  27. 27.
    Gotloib L (1996) Hemofiltration in multiorgan failure syndrome secondary to sepsis: a critical analysis of heterogeneity. Nephron 73: 125–130PubMedCrossRefGoogle Scholar
  28. 28.
    Schetz M, Ferdinande P, Van Den Berghe Verwaest C, Lauvers P (1995) Removal of proinflammatory cytokines with renal replacement therapy: sense or non-sense? Intensive Care Med 21: 169–176PubMedCrossRefGoogle Scholar
  29. 29.
    Stein B, Pfenninger E, Grunert A et al (1990) Influence of continuous arteriovenous haemofiltration on haemodynamics and central blood volume in experimental endotoxic shock. Intensive Care Med 6: 494–499CrossRefGoogle Scholar
  30. 30.
    Bellomo R, Ripping P, Boyce N (1993) Continuous veno-venous hemofiltration with dialysis removes cytokines form the circulation of septic patients. Crit Care Med 21: 522–526PubMedCrossRefGoogle Scholar
  31. 31.
    Rogiers P, Zhang H, Smail N et al (1999) Continuous venovenous hemofiltration improves cardiac function by mechanisms different other than tumor necrosis factor-a attenuation during endotoxic shock. Crit Care Med 27: 1848–1855PubMedCrossRefGoogle Scholar
  32. 32.
    De Vriese AS, Colardyn FA, Philippè JJ et al (1999) Cytokine removal during hemofiltration in septic patients. J Am Soc Nephrol 10: 846–853PubMedGoogle Scholar
  33. 33.
    Rogiers P (1999) Hemofiltration treatment for sepsis. Is it time for controlled trials? Kidney Intern 56[Suppl 72]: S99–S103CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 2001

Authors and Affiliations

  • G. Berlot
  • M. Viviani

There are no affiliations available

Personalised recommendations